Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
14F7 in chronic B-cell lymphoproliferative syndrome
View current
Revisiones
List all revisions
Ver
Compare to current
18 Junio 2018 - 11:32am
por CIM
21 Diciembre 2020 - 11:41am
por lazara
Cambios a
Record Verification Date
-
2018
/
03
/
07
+
2020
/
12
/
21
Cambios a
Next update date
-
2019
/
03
/
07
+
2021
/
12
/
21
Revisión de 21 Diciembre 2020 - 11:41am
14F7 in chronic B-cell lymphoproliferative syndrome
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Acronym of Public Title:
14F7-CLPS
Scientific title:
Phase I / II study of dose escalation and expansion to cohorts, with the therapeutic antibody 14F7h (Anti-NGlicolilGM3) in patients with chronic B-cell lymphoproliferative syndrome, refractory or relapsing
Secondary indentifying numbers:
Not applicable
Issuing authority of the secondary identifying numbers:
Not applicable
Primary sponsor:
Center of Molecular Immunology (CIM)
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Center of Molecular Immunology (CIM) Ministry of Public Health (MINSAP)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Center for State Control of Drugs, Medical Devices and Equipment (CECMED)
Reference number:
In process
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Julio
Midle name:
Damaso
Last name:
Fernandez Aguila
Medical Specialty :
Second Degree Specialist in Hematology
Affiliation:
Gustavo Aledereguia Lima Hospital
Postal address:
Calle 51 A y Avenida 5 de Septiembre
City:
Cienfuegos
País:
Cuba
Zip Code:
55100
Telephone:
+53-043591792
Email address:
jfernandez@gal.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Villa Clara, Arnaldo Milian Castro, Agnerys Lopez Sacerio, MD. 1st Degree Specialist Hematology
Havana, Hermanos Ameijeiras, Kali Cepero LLauger, MD. 1st Degree Specialist Hematology
Havana, Hematology and Immunology Institute, Yusleidy Concepcion Fernandez, MD. 1st Degree Specialist Hematology
Sancti Spiritus, Camilo Cienfuegos, Gloritza Rodriguez Matos, MD. 1st Degree Specialist Hematology
Research ethics committees:
Gustavo Aldereguia Lima, 11/08/2017
Arnaldo Milian Castro, 11/10/2017
Hermanos Ameijeiras, 19/10/2017
Hematology and Immunology Institute, 24/11/2017
Camilo Cienfuegos, 30/11/2017
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
30/05/2018
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Multiple myeloma
Intervention(s):
Stage I 14F mAb intravenously in 5 dose levels (25 mg, 50 mg, 100 mg, 200 mg o 400 mg) every 15 days (5 doses) in induction period and, then every 28 days (4 doses) in maintenance period. Stage II 14F mAb intravenously in 2 dose level for each cohort of patients according to health condition. One dose level will be the Maximum Tolerable Dose (MTD) obtained in stage I and, the other dose level will be the immediate dose lower or higher than MTD according to the criteria of the protocol. Both dose levels will be administered in the same scheme as stage I.
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Stage I Serious Adverse Events (SAE) with causality relationship (Serious Adverse Events those that: 1. Produce death, 2. life-threatening, 3. hospitalization or prolongation of hospitalization indicated, 4. Produce disability / persistent or significant disability, 5. Produce birth defect or congenital anomaly. Will be consider causality relationship when the SAE has definitive/highly probable or probable causality relationship). Measuring time: during and after each administration, throughout the study period until week 52. Stage II Objective response (Complete response y partial response according to the international criteria for each chronic B-cell lymphoproliferative syndrome). Measurement time: weeks 13, 29, 41 and 52
Key secondary outcomes:
Control of the disease (It will to evaluate according to the International response criteria for each chronic B-cell lymphoproliferative syndrome (CLPS) in the categories "Control of the disease" (complete + partial response + stable disease) and "Non-responders" (death + progressive disease) . Measurement time: weeks 13, 29, 41 and 52. Relapse-Free Survival (The time from the date of achievement of a complete response until the date of relapse or death from any cause. Defined only for patients achieving complete response). Measuring time: 52 weeks Event-free survival (The time from treatment began until treatment failure, or relapse or death from any cause). Measurement time: 52 weeks Progression free survival (The time from the start of treatment until to the date of disease progression or death from any cause) Measurement time: 29 and 52 weeks Survival rates (Percentage of patients alive from the diagnosis and the start of treatment). Measuring time: week 29 and week 52 Time to progression (Time measured from the start of treatment to the date of disease progression). Measurement time: 52 weeks Time to treatment failure (Time from the start of treatment to the interruption of treatment for any reason, including disease progression, toxicity or death). Measurement time: 52 weeks Immunogenicity HAHA response (Yes, No. It will be "Yes" when the value of the density of the patient serum is greater than 2 standard deviations of the value of the sera of healthy donor). Measurement time: At baseline, prior to each administration of product, week 29 and week 52. Pharmacokinetics Bioavailability of mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration Volume of distribution of the MAb 14F7hT (numerical value). Measurement time: 1st and 5th administration Constant of elimination of the AcM 14F7hT (numerical value). Measurement time: 1st and 5th administration Maximum concentration of mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration Average life time of the mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration Plasma clearance of mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration Others Expression of surface markers specific to B cells (Percent of expression of markers). Measurement time: at baseline, week13 and week 29 Expression of ganglioside NGGM3 (Negative, weak staining, moderate staining or intense staining). Measurement time: At baseline and, week 29 Safety Adverse Events-AE (Occurrence of any AE (Yes, No), Description (name of AE), duration (Time from the event start until its termination), intensity (Mild, Moderate, Severe, AE that threatens or incapacitates and AE that produces death according to the Common Toxicity Criteria-CTCAE version 4.0 of the National Cancer Institute of the United States), Seriousness (Serious or Not applicable (NA) when the AE is not serious), result (recovered, improved, persists, sequelae), attitude towards treatment (no changes, dose modification, temporary or definitive interruption of treatment under study), causality relationship (Definitive, Very Likely, Probable, Possible, Not related, Unknown), Product Batch (number of the batch used)). Measurement time: In each administration of the product and up to 30 days after the last dose of the product is administered Results of laboratory tests (hematology, blood chemistry and urine). Measurement time: At baseline, weeks 13, 29, 41 and 52. Vital signs (Blood pressure in mmHg, Heart rate in minutes, Temperature in Celsius degrees). In each product administration. Result of the physical examination (It will be evaluated by systems, in Normal or Abnormal, depending on the findings, the category not examined will be used, in case it is not done). Measurement time: At baseline, in each administration of the product and in week 52.
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
18 years
Maximum age:
None
Inclusion criteria:
1. Refractory or relapsing B-cell cell lymphoproliferative syndrome, ganglioside NGlicolilGM3 (NGGM3) positive. 2. Age ≥18 years, any gender and race. 3. ECOG ≤ 3. 4. Life expectancy of 6 months. 5. No candidates for transplant of hematopoietic progenitors or immunochemotherapy schemes not previously used. 6. Four or more weeks from the previous specific therapy (QT, RT, biological therapies) (applicable to patients’ refractory to the previous treatment). 7. Patients with laboratory parameters as detailed below: Hemoglobin ≥ 80 g / L, Absolute neutrophil count ≥ 1.5 x 109 / L, Platelet count ≥ 75 x 109 / L, Liver function (bilirubin, ASAT or ALAT ≤ 2.5 times the normal reference range of each institution), Renal function preserved (creatinine clearance ≥45 mL / min according to the Cockcroft and Gault formula). 8. Voluntary signature of the informed consent model. 9. Subjects of childbearing age and sexually active should agree to use a method of contraception during treatment (criteria valid only for patients of childbearing age).
Exclusion criteria:
1. Pregnant, puerperal or breastfeeding 2. Cytopenia of uncontrolled immune cause 3. Active infection or known positivity for HIV, hepatitis B or C virus 4. Heart failure grade III / IV according to NYHA criteria (New York Heart Association) 5. Chronic decompensated diseases such as: arterial hypertension, diabetes mellitus, ischemic cardiopathy or other symptomatic cardiovascular diseases, epilepsy, obstructive pulmonary disease. 6. Acute allergic states or known hypersensitivity to any component of the formulation under study. 7. Obvious mental disability or other limitation that prevents the patient from signing their consent or hinders the evaluation of the study. 8. Being receiving another research product. 9. Another clinically active neoplasm that needs specific treatment (except basal cell carcinomas or cutaneous carcinomas in situ).
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Treatment
Allocation:
Randomized controlled trial
Masking:
Open
Control group:
Dose comparison
Study design:
Other
Other design:
Dose scale-up (Study in two stages. Stage I: dose escalation and Stage II: basket type design with randomization at two dose levels in 3 patient cohorts)
Phase:
1-2
Target sample size:
142
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Ivis
Middle Name:
Cristina
Last Name:
Mendoza Hernandez
Specialty:
Bachelor in Pharmaceutical Sciences. Master in Clinical Pharmacology
Affiliation:
National Coordinating Center for Clinical Trials (CENCEC)
Postal Address:
5ta A / 60 y 62 Playa
City:
Havana
País:
Cuba
Zip Code:
11300
Telephone:
+53-72164227
Email :
ivis@cencec.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Yanelda
Middle Name:
de los Angeles
Last Name:
Garcia Vega
Specialty:
Bachelor in Biochemistry. Master in Clinical Laboratory Sciences
Affiliation:
Center of Molecular Immunology
Postal Address:
216 & 15, Atabey, Playa
City:
Havana
País:
Cuba
Zip Code:
16040
Telephone:
+53-72717933 Ext 3397
Email :
yaneldag@cim.sld.cu
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000266
Date of Registration in Primary Registry:
07/03/2018
Record Verification Date:
2020/12/21
Next update date:
2021/12/21
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos